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ABSTRACT 
We hypothesized that the increase in mitochondrial proliferation in hearts from 
copper-deficient rats is due to an increase in expression of the transcriptional factor 
Ppargc1a, which regulates transcriptional activity for many of the genes that encode for 
mitochondrial proteins.  In addition to several transcriptional factors implicated in 
mitochondrial biogenesis, we also looked at a number of genes involved in cell cycle 
regulation and fuel substrate utilization.  Long-Evans rats were placed on either a copper-
adequate (n=4) or copper-deficient (n=4) diet 3 days post-weaning and remained on the 
diet for five weeks; their copper deficiency status was confirmed using previously 
established assays.   Custom oligo arrays spotted with genes pertinent to mitochondrial 
biogenesis were hybridized with cRNA probes synthesized from the collected heart 
tissue.  Chemiluminescent array images from both groups were analyzed for gene spot 
intensities and differential gene expression.  Our results did not demonstrate any 
significant increase in Ppargc1a or its implicated targets, as we had predicted.  However, 
consistent with previous data, an up-regulation of genes that encode for collagen type 3, 
fibronectin and elastin were found.  Interestingly, there was also a significant increase in 
the expression of the transcriptional factor Nfκb1 in the copper-deficient treatment 
animals compared to the control group.  The results of this study merit the further 
investigation of the role of ROS with regard to Nfkb1 in the copper deficient rat heart. 
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INTRODUCTION 
 Copper has been established as a necessary component needed for normal 
cardiovascular growth and function. Characteristics of the copper deficient heart include 
the development of concentric cardiac hypertrophy (1,2), weaknesses within the cardiac 
wall structure that can lead to ventricular aneurysms (2-4), and  increased mitochondria 
proliferation (2, 5-7).  Often the mitochondria have disrupted membrane microstructure 
and accumulation of lipid droplets (2). 
 The mechanisms that control mitochondrial biogenesis in the copper-deficient 
heart are not yet clear.  A number of transcriptional factors have been implicated as 
components in the mitochondria biogenesis regulatory pathway. These transcriptional 
factors that have been identified as of yet include, nuclear respiratory factor 1 and 2 
(Nrf1, Nr2f) and mitochondria transcription factor A (Tfam). It has also been shown that 
all of these transcriptional factors require functional activity and binding of another key 
regulatory receptor in order to exert their own activity, the transcriptional co-activator 
peroxisomal-like proliferating related co-activator 1- α (Ppargc1a). 
 Ppargc1a was first identified as a co-activator needed for functional activity of the 
family of peroxisomal proliferating activator receptors (PPARs) (8).  Three PPAR 
isoforms have been identified and all are related to fatty acid metabolism and storage. 
The two main isoforms that are found in the heart include PPAR- α and PPAR-δ/β. 
PPAR- α has been associated with regulation of the fatty acid oxidation pathway, while 
the isoform PPAR- δ/β has been linked to fatty acid storage and transport (9). 
 In the normal adult heart long chain fatty acids are the preferred source of fuel for 
energy metabolism. This is due to the high energy demands of the heart and the 
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efficiency by which fatty acids can provide adequate amounts of ATP, the main source of 
fuel used by the body.  In the failing heart there is a shift in substrate utilization from that 
of primarily lipid oxidation to glucose as the main source of fuel. This shift in energy 
metabolism mimics substrate utilization within the fetal heart and previous studies have 
shown that there is an onset and up-regulation of fetal genes being expressed (10).   The 
increase in mitochondria proliferation and biogenesis has been established as a primary 
disease state of some forms of cardiac hypertrophy, however, it remains unclear in 
regards to abnormal lipid oxidation as to whether or not the shift in energy metabolism 
occurs prior to states of cardiac hypertrophy and the development of heart failure or 
whether it is caused by these disease states. It is also uncertain if the same regulatory 
components that function to regulate mitochondrial proliferation and biogenesis are also 
factors in mitochondrial lipid metabolism. It has been implicated that the PPAR- α and 
PPAR-δ/β transcriptional factors have a role in both mitochondria biogenesis and lipid 
metabolism. This suggests that its co-activator Ppargc1a, which is a known regulator of 
both factors for proliferation and growth of the mitochondria as well as proper function, 
is acting to coordinate this series of events in a concerted fashion and thereby has been 
deemed the “master-regulator” of the mitochondria (9, 11).  
 The purpose of this study is to determine whether gene expression level of 
Ppargc1a are being over-expressed in the copper-deficient rat model heart as well as any 
other possible gene regulation. We propose that there will be a significant up-regulation 
of Ppargc1a which would be reflective of the increase in mitochondria proliferation and 
biogenesis. Other transcriptional factors downstream from PGC1-α should also be up-
regulated according to our experimental hypothesis such as Nrf1, NrF2, and Tfam. We 
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also propose that the targets of Ppargc1a that are involved in lipid oxidation, PPAR- α, 
PPAR-δ/β, and ERR- α may be down-regulated, which would be reflective of the 
dynamic shift in fuel substrate selection. Moreover those genes that are involved in 
glycolysis should be up-regulated in copper-deficiency and the lipid oxidation genes 
should be down-regulated if there is a shift in substrate utilization during copper-
deficiency as proposed. To determine if the genes involved both in mitochondrial 
biogenesis and proliferation were regulated in concert with one another we used 
customized oligo gene arrays in which multiple genes could be analyzed simultaneously. 
Other genes involved with apoptosis, cell cycle, connective tissue metabolism and 
inflammation were also studied as variables of interest. 
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METHODS AND MATERIALS 
Animals and Diets 
 Eight male Long-Evan rats were obtained 3 days post-weanling. Animals were 
purchased from Harlan Sprague Dawley (Indianapolis, IN). Initial weights were recorded 
at the beginning of the study and were recorded once a week for the duration of the study. 
Animals were assigned into two groups of 4 rats each and placed upon either a copper-
adequate diet (CuA) or a copper-deficient diet (CuD). Groups were assigned based upon 
similar weights in order to eliminate any bias of final heart body weight and composition. 
Diets were obtained from Research Diets, Inc. (New Brunswick, NJ). Animals were fed 
their respective diets for 5 weeks, which followed the recommendations of the American 
Institute of Nutrition, consisting of (g/g diet by weight) 0.50 sucrose, 0.20 casein, 0.15 
cornstarch, and 0.05 corn oil as energy sources (12). The control groups (CuA) received 
copper in the form of cupric carbonate at 94.5 µmol Cu/kg diet. The experimental groups 
(CuD) received feed with no added copper. To verify copper composition diets were 
digested with nitric acid and analyzed using flame atomic absorption spectrophotometry 
(Perkin Elmer Model 5000, Norwalk, CT) after the termination of the study.  The 
Institutional Laboratory Animal Care and Use Committee at Kansas State University 
approved the protocol for this study.  
Rats were singly housed in stainless steel cages in a controlled environment with a 
12-hour light: dark cycle at a constant room temperature. All animals had free access to 
deionized-distilled water and food throughout the study.  
After 5 weeks each rat was anesthetized with an intravenous injection of 
thiobutabarbital sodium (Inactin, 100 mg/kg body wt; Research Biochemicals 
  6
  
International, Natick, MA). The thoracic cavities were opened by midline incision and a 
small sample of blood was obtained by cardiac puncture and placed in a heparinized tube 
for hematocrit determination. Hearts were removed, weighed, cut into two equal parts, 
with half placed into RNAlater (Ambion) and the other half frozen in liquid nitrogen .  
Heart tissue was then stored at  - 80°C until processed for RNA extraction.  Livers were 
removed from all rats and placed on ice and frozen at -20 oC for subsequent 
determination of liver Cu-Zn SOD activity. 
 
Hematocrit Assay 
Heparinized blood was transferred to microhematocrit tubes and centrifuged in a 
microcapillary centrifuge for 2 minutes. Hematocrit was determined as the percentage of 
space occupied by packed red blood cells. 
 
Liver Superoxide Dismutase (SOD) assay 
 Liver that was collected from the rats at the termination of the study was used to 
determine liver SOD enzyme activity. One gram of frozen liver tissue from each rat was 
individually homogenized and prepared according to a standard liver SOD protocol (13, 
14). Enzyme activity was analyzed using spectrophotometry. 
 
Customized array development.   
One custom array (SuperArray Biosciences Corporation) was provided for each 
sample for a total of 8 arrays. The custom array layout contained a variety of selected 
genes, including genes that were involved with substrate utilization, enzymes, energy 
  7
  
metabolism, cell cycle regulation, apoptosis, and mitochondria biogenesis. Genes that 
were determined to be targets of interest were complied into a list containing the NCBI 
gene bank number, unigene, and gene symbol and sent to SuperArray, which 
manufactured the custom array layout according to the pre-determined gene list.  One 
hundred and twenty genes were printed on each array. 
 
Total RNA Extraction 
The hearts of each animal were weighed and cut in half: one-half of the heart was 
placed in 10V RNAlater (Ambion), cut into small pieces  (0.5 cm in the smallest 
dimension), and stored at -80 o C.  The other half of the heart was snap frozen in liquid 
nitrogen and also stored at -80 o C.  Total RNA from rat hearts was isolated using the 
RNeasy® Protect Midi Kit (Qiagen), following the manufacturer’s recommendations for 
heart tissue.  Heart tissue (100-150 mg) was either ground in liquid nitrogen and 
homogenized in lysis butter or the small pieces of heart tissue in RNAlater were directly 
homogenized in lysis buffer with a rotor/stator-type homogenizer for 30 seconds on high.      
Proteinase K digestion of the lysate was included to get rid of contaminating proteins and 
to facilitate complete homogenization.  The remaining RNA extraction steps were 
followed as stated in the manufacturer’s protocol.   Total RNA was eluted from the 
columns, quantitated on a Nanodrop spectrophotometer, and aliquoted for further 
applications.  In addition, the quality of the total RNA (~250 ng) was assessed on an 
Agilent 2100 Bioanalyzer Nanochip for subsequent steps and determined to be pure and 
of high-quality.   
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Linear Amplification and Labeling of cRNA Targets for Oligo GEArray®Hybridization 
One microgram of each total RNA sample was used for linear RNA amplification 
using the TrueLabeling-AMP 2.0 Kit (SuperArray Biosciences Corporation).   Briefly, 
primers were annealed to total RNA at 70 oC for 10 minutes, followed by cDNA 
synthesis for 50 min at 42 oC on a thermocycler.  In vitro transcription of biotinylated 
(Biotin-16-UTP, Roche Applied Sciences) cRNA targets was performed for 9 hours at  
37 oC.  The cRNA was then column-purified and eluted in 10 mM Tris, quantified on a 
Nanodrop spectrophotometer, and two micrograms of each biotin labeled cRNA target 
was used for hybridization to eight customized oligo arrays. 
 
cRNA target hybridization and detection  
Arrays were prehybridized at 60 oC for two hours with 2 ml hybridization buffer 
in small hybridization tubes (provided) which were placed in two larger glass 
hybridization bottles in a hybridization oven (five array tubes/hyb bottle).  Two 
micrograms of each cRNA target per array was added to the array tubes and allowed to 
hybridize overnight at 60 oC (SuperArray Biosciences Corp). The next day, post-hybe 
washes were performed at 60 oC with prewarmed 2XSSC/1%SDS and a high stringency 
wash with 0.1X SSC/0.5%SDS.  Arrays were blocked at room temperature and then 
bound to alkaline phosphatase (AP) -conjugated streptavidin at 1:8000.  After AP 
labeling, the arrays were washed in detection solutions and exposed with 1:1 CDP-
Star:Buffer G in  pairs (one copper deficient array/one control array per five exposures).  
Each pair of arrays was exposed for 15 minutes under a FluorChem™ 8800 Imaging 
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System (Alpha Innotec Corporation, San Leandro, CA).  The remaining arrays were left 
in detection buffer G until exposed, in pairs.  Captured array images were uploaded into 
GEArray Suite Analysis (SuperArray Biosciences Corp) for analysis.  Once uploaded 
into GEArray Suite, the arrays were normalized using inter-quartile normalization and 
background was substracted.  The copper- deficient array spots were compared to the 
control array spots to determine fold change differences in gene expression as determined 
by spot intensities/ratios.   
 
Real-time qPCR 
 
 In a second study, real-time quantitative PCR was used to determine fold changes 
in Nfkb1 (p105 subunit) and PGC-1 alpha using Taqman Gene Expression Assays 
(Applied Biosystems, Foster City, CA).  The Assay ID number for Nfkb1was 
Rn01399583_m1 and a final concentration of 900nm each primer and 250 nm probe was  
used.  The PGC-1alpha Assay ID number was Rn00676177_g1 and primer and probes 
was also used at 900nm of each primer and 250 nm probe final concentration.  Both gene 
expression assays had a FAM reporter dye at the 5’end of the Taqman MGB probe and a 
nonfluorescent quencher at the 3’end of the probe.  Rat heart cDNA was reverse 
transcribed from total RNA using random hexamer priming (SuperScript III First-Strand 
Synthesis System for RT-PCR, Invitrogen, Carlsbad, CA), as 18S eukaryotic rRNA 
(VIC-MGB labeled) was used as an endogenous control for relative quantitation and to 
determine fold change by the ∆∆CT (comparative) method.  All cDNA samples were 
adjusted to the highest 18S Ct value (or sample with the lowest concentration).  The PCR 
reaction was run on an ABI 7000 Prism Detection System (Applied Biosystems) using 
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the following cycling conditions: 15 seconds@ 95oC and 1 min @60oC (40 cycles).  A 
semi-log regression curve of ∆CT vs. input amount of cDNA template was plotted to 
ensure the efficiency of the target gene (Nfkb1 or PGC-1 alpha) and reference gene (18S 
rRNA) were approximately equal (or slope ≤0.1) and that ∆∆Ct calculations were valid.   
 
Statistical Analysis 
 Due to non-parametric data, the F-rank protected T-test was employed as the 
statistical means of analysis. Total binding intensity (pixels) was averaged for each group 
and analyzed. Results were reported as significant using a p-value of 0.05. Results were 
reported to be a significant trend using a p-value of p< 0.10.  
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RESULTS 
 Final heart weights between the two groups indicated that the CuD rats had a 
lower mean body weight (p ≤ 0.0001), a higher mean heart weight (p ≤ 0.0001), and the 
final heart weight to body weight measurements (HW:BW) indicated that the CuD rats 
had a significantly higher ratio (p ≤ 0.05) (Table 1). Analysis of the hematocrit assay and 
liver Cu,Zn SOD assay demonstrated that there was a significant decrease of the means in 
the CuD group (p ≤ 0.05 and 0.001, respectively).   
Gene expression results from this study are presented by degree of significance of 
fold change. In one series of results we reported those genes that were significantly 
different from one another by treatment (p ≤ 0.05) and that had a fold increase or 
decrease of at least 50% (Table 2). A second set of results are presented where genes 
were statistically significant by treatment (p ≤ 0.05) but did not have a fold change of 
greater or less than 50% (Table 2). A third set of data is presented in which there was a 
significant trend in data between the two treatment groups, indicted by p ≤ 0.05-0.10 
(Table 3).  
 Genes that demonstrated a significant difference (p≤ 0.05) are shown in Table 2. 
Genes that were different and had a fold increase or decrease of at least 50%  included: 
nuclear factor κ B1, collagen type 3a1, early growth response 1, E2F transcription factor 
1, myelocytomatosis viral oncogene homolog, matrix metalloprotidase 12, carnitine 
palmitoyltransferase, and O-6-methylguanine DNA methyltransferase. In addition, genes 
that demonstrated a significant difference (p ≤ 0.05) as determined by the F-rank test but 
did not display a fold change induction of greater or less than 50% as compared to the 
controls are also shown in Table 2. These genes were Kirsten rat sarcoma viral oncogene 
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homologue 2 (active), insulin-like growth factor binding protein, caspase 8, elastin, and 
cyclin-dependent kinase 6. 
Genes that demonstrated a trend (p=0.05-0.10) and displayed a fold change 
induction of greater or less than 50% as compared to the controls are shown in Table 3. 
Observed genes that met both of these criteria include interleukin 2, cyclin-dependent 
kinase inhibitor 2b (Cdkn2b), fibronectin 1,  DNA-inducible transcript 3, and caspase 9. 
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DISCUSSION 
 Previous studies have shown that rats fed a copper-deficient diet demonstrate 
decreased copper-dependent enzyme activity (15), impaired mitochondrial respiration 
(16), abnormal membrane pathology (3), and increased mitochondrial biogenesis (17). 
The copper-deficient rat model displays characteristics in the changes and pathology of 
the heart structure that mimics pressure overload (18). 
 Consistent with this altered state, analysis of our data showed that there was a 
significant increase in the connective tissues elastin and collagen type 3a transcripts, 
which is a primary collagen type found in the cardiac tissue. These connective tissues 
have previously been represented to be up-regulated in the copper-deficient heart (2, 19). 
It was also shown in this study that the connective tissue fibronectin showed a trend 
towards being significantly up-regulated (20, 21), which is reflective of our findings 
regarding copper-deficiency and enzyme activity, in addition to previously reported data 
(15).  
 In recent studies much attention has been directed towards the increase in 
mitochondrial biogenesis within the heart and the regulating factors governing this 
pathway. Targets of these studies have included the transcriptional factors mitochondrial 
transcription factor A (Tfam), Nrf1, Nr2f, PPAR-α, and Ppargc1a and their interactions 
as possible signaling pathways that are responsible for the demonstrated pathologies. 
Previous hypotheses suggested the interactions between mtTFA and Nrf1, Nr2f as a 
possible mechanism for enhancing mitochondrial biogenesis within the copper-deficient 
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heart. Most notably Mao et al. (22, 23) found that rats fed a CuD diet for five weeks 
displayed significantly higher amounts of Tfam proteins expressed within the CuD hearts, 
however there was no change in the expression of Nrf1 or Nr2f. These findings have not 
shown to be consistent from study to study, and Mao et al., (23) did implicate that these 
findings may be due to a transient change that is occurs in a time-dependent manner 
within a failing heart, with the up-regulation of Nrf1 and Nr2f occurring early in the 
development of heart failure and returning to normal or near normal levels after the initial 
change (23). Our current findings did not demonstrate any significant difference among 
the treatment and control groups for any of the three transcriptional factors involved in 
mitochondrial biogenesis. 
The various PPAR isoforms regulate fatty acid metabolism in various tissues 
including the heart.  A co-activator is needed for the PPAR isoforms to function as 
promoters.  The transcriptional co-activator that was identified as the regulating factor 
within the heart was peroxisomal proliferator activated-receptor 1-alpha (Ppargc1a). (8).  
Further studies within the Kelly lab at Washington University (St. Louis, MO) found that 
PGC-1-α was directly linked to PPAR-alpha (24) and appeared to increase its activity and 
function with regards to mitochondrial biogenesis control (11, 25). Similar studies also 
demonstrated that forced over-expression of Ppargc1a in vivo resulted in an enhanced 
expression within cardiomyocytes and increased mitochondria gene transcriptional levels 
within the cardiac tissue (24). Several studies have now reported that Ppargc1a directly 
targets Nrf1, Nr2f, Tfam, and the PPAR family and appears to enhance transcriptional 
activity. Our findings were not consistent with these previous reports. While we did 
observe an increased fold change in Ppargc1a within the CuD treatment group, it did not 
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prove to be significant. Further studies in our lab using real-time quantitative PCR have 
not yet shown clear, consistent changes in Ppargc1a expression.  
  The preferred energy substrate of the heart is fatty acids. Hearts that display 
cardiac hypertrophy with heart failure demonstrate a profound decrease in lipid oxidation 
and increase glucose utilization, which mimics energy metabolism within the fetal heart 
(10). As mentioned above, genes that encode for mitochondrial fatty acid metabolism are 
regulated by the peroxisome-proliferating activated receptors (PPARs) a family of 
transcriptional factors, which in addition to being linked to fatty acid metabolism, have 
been suggested to play a key role in mitochondrial biogenesis. There are three isoforms 
of PPARs, all of which are induced by fatty acids and exert their function by binding to 
the retinoic receptor (RXR) as well as a repeating binding sequence motif (26). PPAR-α 
and more recently the isoform PPAR-δ have been implicated as the main isoforms 
present in cardiac as well as brown adipose tissue and are responsible for targeting the 
promoter region of key mitochondrial enzymes to regulate cardiac energy metabolism. 
PPAR-α is suggested to be the main isoform responsible for fat metabolism within the 
heart and has been shown to be involved in the majority of processes governing fatty acid 
catabolism.  None of these genes appeared to be differentially expressed in our study. 
 Our results indicated that there was a significant increase in the translocation 
protein carnitine palmytioltransferase 1 (CPT-1) which is associated with fatty acid 
metabolism and functions to shuttle the fatty acids across the mitochondrial membrane to 
the electron transport chain. This up-regulation of CPT-1 that we observed may be 
explained by the increase in total mitochondria within the heart and not to an increase in 
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free fatty acid mobilization. This finding is consistent with prior studies related to the 
copper-deficient heart and cardiac hypertrophy (1, 27).  
 
A novel finding reported in this study in regards to the copper-deficient rat model 
and heart failure was the up-regulation of Nfκb1. Our preliminary studies using real time 
PCR supports this finding for Nfκb1.  Nfκb1 is a transcriptional factor that has been 
implicated as a regulator of multiple factors such as Ppargc1a, PPARs, Nrf1, Nr2f, 
HNF4, and MEF2. Nfκb1 has also been suggested to be a key regulator of a number of 
enzymes. Nbκb1 is a major element of the cellular growth, inflammatory, and apoptotic 
pathways (28). We found significant upregulation in the mRNA expression levels for a 
variety of known genes associated with cell survival and DNA repair such as caspase 9 
and O-6-methylguanine-DNA-methyltransferase enzyme, respectively. We also found an 
up-regulation trend in the anti-apoptotic/cell survival genes Mdm2, which function to 
inhibit p53 growth suppression, BCL2 and Gadd45 both of which may mediate a delay in 
G2 to M cell cycle progression or may induce DNA repair. Also, we report that data 
collected and analyzed from the copper-deficient hearts displayed a decrease that was 
near significant in the apoptotic genes caspase 8. There was also an observed increase in 
a number of genes that are related to cell growth and proliferation such as Igfb3, Kras2 
and Myc (both oncogenes, also involved in cell survival), Erg1, E2F1, and Vegf.  
Nfκb1 has recently received attention as a component of the pathway governing 
cardiac hypertrophy and subsequent heart failure signaling. One of the major ways that 
Nfκb1 is induced is via reactive oxidative species (ROS). ROS are a by-product of the 
oxidative/phosphorylation process within the mitochondria. Copper-deficient rats 
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produce more reactive oxygen species and results in lipid peroxidation in the heart (29, 
30) and one report suggests that NFkB expression is related to copper status (31).  In 
copper-deficiency a possible increase in glucose utilization could lead to a decrease in the 
membrane efficiency to produce adequate energy to meet metabolic demands. This 
further leads to an increase in the electrons retained in the electron transport chain and 
may lead to an increase in ROS formation. Other studies have shown that activation of 
Nbκb1 is required for the development of cardiac hypertrophy in vivo (32) as well as 
needed for hypertrophic growth of ventricular cardiomyocytes in culture (32, 33). Studies 
using aortic banding-induced cardiac hypertrophy have demonstrated increase expression 
levels of Nfκb1 (32), while studies that have used NFκB inhibition decreases the 
hypertrophic response of cardiac myocytes.  
 Finally, the negative observations reported here on genes involved with glucose 
and fatty acid oxidation may simply mean that there is no shift in substrate utilization.  
To our knowledge, there have been any reported studies on fatty acid and/or glucose 
oxidation in the heart during copper-deficiency.  The increased number of mitochondria 
observed in copper-deficiency may be sufficient enough to met energy demands.  The 
role of Nfκb1 in copper-deficiency and cardiac hypertrophy may b a novel line of 
inquiry. 
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Functional category Gene GenBank 
number 
Substrate utilization -Medium chain acyl dehydrogenase 
-Long chain acyl dehydrogenase 
-PPAR-alpha 
-PPAR-delta 
-PPAR-gamma 
-Retinoic acid receptor-alpha 
-Retinoic acid receptor-gamma 
-phosphoenolpyruvate carboxykinase 
-Carnitine palmitoyltransferase 
-Insulin-like growth factor b3 
 
NM_016986 
NM_012819 
NM_013196
NM_013141 
NM_013124 
NM_031528 
XM_217064 
NM_198780 
NM_013200 
NM_012588 
Mitochondrial 
biogenesis 
-PGC-1alpha 
-mitochondrial transcription factor A -
-Nuclear respiratory factor-1 
-Nuclear respiratory factor-2 
 
NM_031347 
NM_031326 
XM_231566. 
XM_575228 
Electron transport -oligomycin sensitivity conferring 
     protein 
-inhibitor of ATP hydrolysis  by the 
     mitochondrial A complex 
-cytochrome C oxidase subunit II 
-cytochrome C oxidase subunit IV 
-ATP synthase beta subunit  
-ATP synthase, H+ transporting,  
    mitochondrial F1 complex, delta 
    subunit 
NM_138883 
 
NM_012915 
 
NC_001665 
NM_017202 
M19044 
NM_139106 
Cardiac Proteins -troponin C, cardiac/slow skeletal  
-troponin I, cardiac  
-troponin T2, cardiac  
-myoglobin  
-cardiotrophin 1 
-natriuretic peptide precursor type A 
XM_214266 
NM_017144 
NM_012676 
NM_021588 
NM_017129  
NM_012612 
Connective Tissue -collagen alpha1 type I  
-collagen, type III, alpha 1 
-alpha-3 type IV collagen 
-fibronectin 1 
-elastin 
Z78279 
NM_032085 
XM_343607 
NM_019143 
NM_012722 
Apoptosis and cell 
cycle 
 
 
 
-nuclear factor kappa B, p105 subunit 
-BAX 
-BCL2 
-Caspase 8 
-Caspase 9 
XM_342346 
NM_017059 
NM_016993 
NM_022277 
NM_031632 
  19
  
 
 
Apoptosis and cell 
cycle (con’t) 
-Cyclin Dependent kinase 6 
 
-O-6-methylguanine DNA 
    methyltransferase                                
-E2F transcription factor 1 
-Early growth response 1 
-Kirsten rat sarcoma viral oncogene 
    homologue 2 (active) 
-cyclin-dependent kinase inhibitor 2B 
-Myelocytomatosis viral oncogene 
    homolog 
-DNA-inducible transcript 3 
 
AF352168 
 
NM_012861 
 
XM_230765 
NM_012551 
NM_031515 
 
NM_130812 
NM_012603 
 
NM_024134 
Copper chaperone 
proteins 
-SCO cytochrome oxidase deficient 
    homolog 1 (yeast) 
-endothelial growth factor 1 (77% 
    similar to human SCO2) 
-COX17 homolog, cytochrome c 
    oxidase assembly protein (yeast)  
    (Cox17) 
-copper chaperone for superoxide 
    dismutase  
-ATX1 (antioxidant protein 1)  
    homolog 1 (yeast)  
-estrogen- related receptor, alpha 
-superoxide dismutase 1 
 
NM_004589 
 
NM_005138 
 
NM_053540 
 
NM_053425 
 
NM_053359 
 
NM_001008511 
NM_017050 
Other -Matrix Metalloprotidase 12 
    (proteolytic enzyme) 
-Interleukin 2 (Immune response) 
 
NM_053963 
 
NM_053836 
Endogenous  controls* -Glyceraldehyde-3-phosphate 
     dehydrogenase  
-Aldolase A 
-Lactate dehydrogenase A  
-Ribosomal protein L32 
NM_017008 
 
NM_012495 
NM_017025 
NM_013226 
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Table 1. Indices of copper deficiency in male Long Evans rats fed a 5 week 
copper deficient (CuD) diet. Values expressed as means ± standard error (S.E.). 
 
 
Variable Control (CuA) 
Mean ± S.E. 
Copper-deficient 
(CuD) Mean ±S.E. 
Final Heart Weight 
(g)***
1.23 ± 0.048 1.60 ± 0.198 
Body Weight (g) *** 296.72 ± 11.5  166.02 ± 8.7  
HW:BW ratio* 0.0060 ± 0.002  0.0041 ± 0.0011  
Hematocrit* 41.3 ± 2.1  31.2 ± 3.7  
Liver Cu,Zn SOD 
(U/g wet wt) **
10278.80 ± 8.123  2746.4 ± 11.475  
 
 
 
 
 
***p < 0.0001 
  **p < 0.001 
    *p < 0.05
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Table 2. Genes that showed a significant difference between the CuD treatment and the 
CuA control groups with a p-Value < 0.05, as determined by the F-rank t-test. Control 
value is equal to 1.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
    
 
 
                             
   * p < 0.05 
Observed Gene Fold 
Change* 
 
Nuclear factor kappa b 1 2.43*
Collagen type 3a1 2.17*
Early growth response 1 1.77*
E2F transcription factor 
1 
1.65*
Myelocytomatosis viral 
oncogene homolog 
1.56*
Matrix Metalloprotidase 
12 
1.52*
Carnitine 
palmitoyltransferase  
1.52*
O-6-methylguanine 
DNA-methyltransferase 
1.51*
Kirsten rat sarcoma viral 
oncogene homologue 2 
(active) 
1.37**
Insulin-like 
 growth factor b3 
1.27* 
 
Caspase 8 1.14*
Elastin 1.11*
Cyclin Dependent kinase 
6 
0.73*
 ** p < 0.01  
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Table 3. Genes within the CuD treatment group that were observed to have a fold change 
50% greater or less than the expressed control group. These genes were found to 
demonstrate a trend towards significance, at P = 0.05-0.010, as determined by the F-
ranked t-test. Control is equal to 1.0. 
 
 
 
 
 
 
 
 
 
 
 
Observed Gene Fold Change 
CuD vs. CuA*
Interleukin 2 2.97 
Cdkn2b 2.24 
Fibronectin 1 2.17 
DNA-inducible transcript 3 1.88 
Caspase 9 1.79 
*p = 0.05 – 0.10
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